Treatment paradigms in Parkinson's Disease and Covid-19

TY - CHAP

T1 - Treatment paradigms in Parkinson's Disease and Covid-19

AU - Boura, Iro

AU - Batzu, Lucia

AU - Dietrichs, Espen

AU - Ray Chaudhuri, Kallol

N1 - Publisher Copyright: © 2022 Elsevier Inc.

PY - 2022/1

Y1 - 2022/1

N2 - People with Parkinson's Disease (PwP) may be at higher risk for complications from the Coronavirus Disease 2019 (Covid-19) due to older age and to the multi-faceted nature of Parkinson's Disease (PD) per se, presenting with a variety of motor and non-motor symptoms. Those on advanced therapies may be particularly vulnerable. Taking the above into consideration, along with the potential multi-systemic impact of Covid-19 on affected patients and the complications of hospitalization, we are providing an evidence-based guidance to ensure a high standard of care for PwP affected by Covid-19 with varying severity of the condition. Adherence to the dopaminergic medication of PwP, without abrupt modifications in dosage and frequency, is of utmost importance, while potential interactions with newly introduced drugs should always be considered. Treating physicians should be cautious to acknowledge and timely address any potential complications, while consultation by a neurologist, preferably with special knowledge on movement disorders, is advised for patients admitted in non-neurological wards. Non-pharmacological approaches, including the patient's mobilization, falls prevention, good sleep hygiene, emotional support, and adequate nutritional and fluid intake, are essential and the role of telemedicine services should be strengthened and encouraged.

AB - People with Parkinson's Disease (PwP) may be at higher risk for complications from the Coronavirus Disease 2019 (Covid-19) due to older age and to the multi-faceted nature of Parkinson's Disease (PD) per se, presenting with a variety of motor and non-motor symptoms. Those on advanced therapies may be particularly vulnerable. Taking the above into consideration, along with the potential multi-systemic impact of Covid-19 on affected patients and the complications of hospitalization, we are providing an evidence-based guidance to ensure a high standard of care for PwP affected by Covid-19 with varying severity of the condition. Adherence to the dopaminergic medication of PwP, without abrupt modifications in dosage and frequency, is of utmost importance, while potential interactions with newly introduced drugs should always be considered. Treating physicians should be cautious to acknowledge and timely address any potential complications, while consultation by a neurologist, preferably with special knowledge on movement disorders, is advised for patients admitted in non-neurological wards. Non-pharmacological approaches, including the patient's mobilization, falls prevention, good sleep hygiene, emotional support, and adequate nutritional and fluid intake, are essential and the role of telemedicine services should be strengthened and encouraged.

KW - Covid

KW - Hospitalization

KW - Management

KW - Pandemic

KW - Parkinson

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85130952300&partnerID=8YFLogxK

U2 - 10.1016/bs.irn.2022.03.002

DO - 10.1016/bs.irn.2022.03.002

M3 - Chapter

C2 - 36208898

AN - SCOPUS:85130952300

SN - 9780323991735

T3 - International Review of Neurobiology

SP - 135

EP - 171

BT - Covid-19 and Parkinsonism

A2 - Chaudhuri, K Ray

A2 - Rodríguez-Violante, Mayela

A2 - Antonini, Angelo

A2 - Boura, Iro

PB - ACADEMIC PRESS INC

ER -